Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Wednesday, November 23, 2011
Plasma MicroRNA Panel ID’d for Diagnosing Hepatocellular Cancer
Jian Zhou, M.D., Ph.D., from Fudan University in Shanghai, China, and colleagues sought to identify plasma microRNAs for diagnosing HBV-related HCC. A total of 934 participants, including healthy individuals, and those with chronic hepatitis B, cirrhosis, and HBV-related HCC, were selected between August 2008 and June 2010. Initially, 723 microRNAs in 137 plasma samples were screened using a microarray to diagnose HCC. The expression of selected microRNAs was subsequently evaluated using a quantitative reverse-transcriptase polymerase chain reaction assay. A training cohort comprising 407 individuals was used to create a logistic regression model, which was then validated using an independent cohort of 390 individuals. The diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUC).